Agios Pharmaceuticals (NASDAQ: AGIO) net income
Agios Pharmaceuticals reported a net loss of $412.8m for fiscal 2025; in fiscal 2024 it reported a net profit of $673.7m. Earnings per share were −$7.12.
Agios Pharmaceuticals's best year of the last 10 was fiscal 2021. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$412.8m | −161.3% | −764.0% | −$7.12 |
| 2024 | $673.7m | — | 1,845.9% | $11.86 |
| 2023 | −$352.1m | — | −1,312.6% | −$6.33 |
| 2022 | −$231.8m | −114.4% | −1,627.8% | −$4.23 |
| 2021 | $1,605m | — | — | $26.55 |
| 2020 | −$327.4m | — | — | −$4.74 |
| 2019 | −$411.5m | — | −349.0% | −$6.86 |
| 2018 | −$346.0m | — | −366.6% | — |
| 2017 | −$314.7m | — | −731.6% | — |
| 2016 | −$198.5m | — | −284.0% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Agios Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Agios Pharmaceuticals ranks 468th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Agios Pharmaceuticals, −764.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 466th | Grail | −$408.4m | −277.5% |
| 467th | Intellia Therapeutics | −$412.7m | −609.9% |
| 468th | Agios Pharmaceuticals | −$412.8m | −764.0% |
| 469th | Guardant Health | −$416.3m | −42.4% |
| 470th | Vir Biotechnology | −$438.0m | −638.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Agios Pharmaceuticals
- How much did Agios Pharmaceuticals earn in fiscal 2025?
- Agios Pharmaceuticals reported a net loss of $412.8m for fiscal 2025. In fiscal 2024 it reported a net profit of $673.7m.
- What are the earnings per share of Agios Pharmaceuticals?
- They were −$7.12 in fiscal 2025, compared with $11.86 in fiscal 2024.
- What was the most profitable year for Agios Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2021, with $1,605m.
- Where does Agios Pharmaceuticals rank in its sector by net income?
- It ranks 468th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Agios Pharmaceuticals come from?
- From the annual report (Form 10-K) that Agios Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Agios Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Agios Pharmaceuticals: the Agios Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.